GlycoMimetics (NASDAQ: GLYC) has recently received a number of price target changes and ratings updates:
- 8/2/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 7/26/2024 – GlycoMimetics was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating.
- 7/25/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 7/17/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 7/9/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 7/1/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/23/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 6/15/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
GlycoMimetics Trading Up 0.7 %
NASDAQ:GLYC traded up $0.00 during midday trading on Wednesday, hitting $0.18. 743,676 shares of the company traded hands, compared to its average volume of 2,217,792. The firm has a market capitalization of $11.64 million, a P/E ratio of -0.31 and a beta of 2.19. The firm’s fifty day moving average is $0.27 and its 200-day moving average is $1.57. GlycoMimetics, Inc. has a 12-month low of $0.17 and a 12-month high of $3.53.
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). On average, research analysts expect that GlycoMimetics, Inc. will post -0.61 EPS for the current fiscal year.
Insider Transactions at GlycoMimetics
Hedge Funds Weigh In On GlycoMimetics
Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC grew its position in shares of GlycoMimetics by 61.8% in the second quarter. Acadian Asset Management LLC now owns 534,753 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 204,227 shares during the period. Advisor OS LLC purchased a new position in GlycoMimetics in the 4th quarter valued at about $238,000. Finally, Vanguard Group Inc. boosted its holdings in GlycoMimetics by 14.0% in the 1st quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock worth $8,286,000 after buying an additional 340,112 shares during the last quarter. Hedge funds and other institutional investors own 75.19% of the company’s stock.
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Read More
- Five stocks we like better than GlycoMimetics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- What Are Bonds? A High-Level Overview
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- Most active stocks: Dollar volume vs share volume
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for GlycoMimetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.